Aldeyra Therapeutics will prioritize its ocular disease programs while placing on hold clinical development in other fields as part of a strategic prioritization program, according to a press release.
The company will focus on allergic conjunctivitis, dry eye disease and proliferative vitreoretinopathy late-stage programs to extend its cash runway through the end of 2021, the release said.
James A. Gow, MD, an ophthalmology drug development expert, has been named as senior vice president of clinical development. He previously served as vice president and global development lead for lifitegrast
Uncategorized